NCT02696785

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 341 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).

Conditions

• Spondyloarthritis

Interventions

Type	Name	Description
DRUG	Ixekizumab	Administered SC
DRUG	Placebo	Administered SC
DRUG	Adalimumab	Administered SC

Timeline

• Start date: 2016-05-02
• Primary completion: 2017-12-08
• Completion: 2018-10-17
• First posted: 2016-03-02
• Last updated: 2019-11-19
• Results posted: 2019-11-19

Locations

28 sites across 7 countries: United States, Czechia, Germany, Japan, Netherlands, South Korea, Taiwan